How to Get Belsomra (Suvorexant) in Ohio

What Is Suvorexant and How Does It Work?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks the wake-promoting neuropeptides orexin-A and orexin-B. The FDA approved Belsomra in August 2014 for adults with insomnia characterized by difficulty falling asleep or staying asleep 1. Unlike benzodiazepines or Z-drugs, DORAs do not act on GABA receptors.

The mechanism matters clinically. Rather than sedating the entire brain, suvorexant selectively dials down the arousal signal. The key phase III trial by Herring et al. (N=1,021) demonstrated that suvorexant 40 mg and 20 mg both significantly improved subjective total sleep time versus placebo at four weeks, with a mean increase of approximately 25 minutes for the 20 mg dose 2. A separate 12-month safety extension confirmed sustained efficacy without evidence of rebound insomnia after discontinuation 3. The American Academy of Sleep Medicine (AASM) conditionally recommends suvorexant for sleep-maintenance insomnia in adults, noting moderate-quality evidence supporting its use 4.

Suvorexant carries a lower abuse liability than traditional hypnotics. An FDA advisory committee review found its Schedule IV classification appropriate based on human abuse-potential studies showing limited euphoria at supratherapeutic doses 1. That scheduling decision directly affects how Ohio regulates its prescribing.

Ohio Telehealth Prescribing Rules for Schedule IV Drugs

Yes, Ohio allows telehealth prescribing of Belsomra. Ohio law permits prescribers to issue controlled substance prescriptions via telehealth as long as the encounter includes a synchronous audio-video visit 5. A phone-only call does not satisfy this requirement for initial prescriptions of controlled substances.

The Ohio State Medical Board requires that the prescriber establish a legitimate prescriber-patient relationship before issuing a Schedule IV prescription 6. This means the telehealth provider must conduct a clinical evaluation, review relevant history, and document the encounter as they would for an in-person visit. Ohio does not require an in-person visit before the first telehealth prescription of a Schedule IV substance, provided the audio-video standard is met.

For Ohio residents, this opens a practical pathway. A board-certified sleep medicine physician or primary care provider licensed in Ohio can evaluate you over video, confirm an insomnia diagnosis, and transmit a Belsomra prescription electronically to any Ohio pharmacy. The DEA's requirement for electronic prescribing of controlled substances (EPCS) applies, so your prescriber must use a CEHRT-certified e-prescribing system 7.

Who Can Prescribe Belsomra in Ohio?

Three categories of licensed prescribers in Ohio have authority to prescribe Schedule IV controlled substances. MDs and DOs hold independent prescribing authority with no supervisory requirements 6. Nurse practitioners with a Certificate to Prescribe (CTP) gained full independent prescribing authority for Schedule III through V drugs under Ohio Senate Bill 131, effective in 2024, removing the previous collaborative agreement requirement for experienced NPs 8. Physician assistants may prescribe Schedule IV drugs under a supervisory agreement with a physician, with no limit on the number of PAs a physician can supervise 6.

This is straightforward for most patients. If you see a sleep specialist, internist, family medicine physician, psychiatrist, NP, or PA licensed in Ohio, they can write the prescription. There is no Ohio-specific certification or additional DEA waiver required for suvorexant beyond the standard Schedule IV authority.

The Prescription Process: From Evaluation to Pharmacy

Getting Belsomra in Ohio follows a defined sequence. The clinical evaluation comes first. Your provider will assess sleep-onset latency, wake-after-sleep-onset time, and daytime functioning. The AASM clinical practice guideline recommends that cognitive behavioral therapy for insomnia (CBT-I) be offered as initial treatment before pharmacotherapy 4. Many insurers require documentation that CBT-I was offered, attempted, or deemed inappropriate before approving Belsomra.

No specific laboratory tests are mandated before starting suvorexant. However, providers commonly order a thyroid panel (TSH) and a basic metabolic panel to rule out medical causes of insomnia 9. If obstructive sleep apnea is suspected, a home sleep test or polysomnography may be required first, since the Belsomra prescribing information notes the drug has not been studied in patients with severe OSA 1.

After the evaluation, the prescriber selects a starting dose. The FDA-recommended starting dose is 10 mg, taken no more than once per night within 30 minutes of bedtime, with at least 7 hours remaining before planned waking 1. The dose can be increased to 20 mg if 10 mg is tolerated but insufficiently effective. The prescriber then e-prescribes the medication to your chosen Ohio pharmacy.

Typical turnaround from telehealth visit to pharmacy pickup is 24 to 48 hours when no prior authorization is needed. If prior authorization is required, add 1 to 3 business days.

Ohio Medicaid Coverage: A Significant Limitation

Ohio Medicaid does not cover Belsomra for insomnia. The Ohio Department of Medicaid preferred drug list restricts suvorexant coverage to patients with type 2 diabetes only, reflecting a narrow formulary decision 10. This means Ohio Medicaid beneficiaries with primary insomnia will receive a denial if their provider submits a standard prior authorization for Belsomra.

For Medicaid patients, alternatives include generic trazodone, generic zolpidem, and generic eszopiclone, all of which appear on the Ohio Medicaid preferred drug list. If a provider believes suvorexant is medically necessary despite the formulary restriction, they can submit a non-formulary exception request, though approval rates for these requests are low without documented failure of at least two preferred agents.

Patients on Managed Medicaid plans (such as CareSource, Molina, or UnitedHealthcare Community Plan in Ohio) should check their specific plan's formulary, as managed care organizations may apply different step therapy requirements 10.

Commercial Insurance and Prior Authorization

Most commercial insurers in Ohio cover Belsomra but require prior authorization. The typical prior authorization criteria include a confirmed insomnia diagnosis (ICD-10 G47.00 or G47.01), documentation that the patient tried or has a contraindication to at least one generic sleep aid (zolpidem or eszopiclone), and a statement that CBT-I was discussed or attempted 11.

The process works like this: your prescriber submits the PA request electronically or by fax. The insurer's pharmacy benefit manager reviews it against their step therapy criteria. Approval or denial typically comes within 24 to 72 hours. If denied, your prescriber can file a peer-to-peer review with the insurer's medical director.

With commercial insurance and an approved PA, the typical copay for brand-name Belsomra ranges from $30 to $75 per month depending on the plan tier. Without insurance, the retail price in Ohio pharmacies averages $400 to $500 for a 30-day supply. Merck's patient assistance program may cover eligible uninsured patients earning below 400% of the federal poverty level 12.

503A Compounding Pharmacies in Ohio

Ohio-licensed 503A compounding pharmacies can prepare suvorexant formulations pursuant to a valid patient-specific prescription. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies compound medications for individual patients based on a prescriber's order 13. Ohio's Board of Pharmacy regulates these facilities under Ohio Administrative Code Chapter 4729 14.

A compounded suvorexant preparation may be useful in specific situations: if a patient needs a dose not commercially available (such as 7.5 mg), if they cannot swallow tablets and need a liquid formulation, or if they have an allergy to an inactive ingredient in the brand product. The compounded product is not AB-rated to Belsomra and has not undergone FDA bioequivalence testing, so prescribers should document the clinical rationale.

Ohio 503A pharmacies can ship compounded medications within the state. Interstate shipping of 503A compounded drugs is restricted to states where the pharmacy holds a nonresident license, so patients should confirm shipping eligibility if using an out-of-state compounder 13.

Safety Profile and Monitoring

Suvorexant's most common adverse effects in clinical trials were somnolence (7% vs. 3% placebo), headache, and dizziness 1. The FDA label carries warnings about next-morning impairment, sleep paralysis, hypnagogic hallucinations, and complex sleep behaviors (sleepwalking, sleep-driving). A pooled safety analysis across phase III trials (N=3,291) found no significant increase in falls or cognitive impairment compared with placebo in adults aged 18 to 64 2.

In older adults, a dedicated trial in patients aged 65 and older (N=792) showed that suvorexant 30 mg and 15 mg improved wake-after-sleep-onset by 36.4 and 20.4 minutes versus placebo, respectively, with a safety profile comparable to the general adult population 15. The recommended starting dose for elderly patients is 5 mg 1.

Drug interactions are relevant for Ohio prescribers. Suvorexant is metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) are contraindicated with suvorexant, and moderate inhibitors (diltiazem, erythromycin, fluconazole) require a dose reduction to 5 mg 1. The prescribing clinician should review the patient's medication list for CYP3A4 interactions before writing the prescription.

A 2020 meta-analysis published in the Journal of Clinical Sleep Medicine evaluated all three FDA-approved DORAs and found suvorexant associated with a number needed to treat (NNT) of 8 for clinically meaningful improvement in sleep maintenance 16. This positions it as a reasonable second-line option when first-line agents fail or are contraindicated.

How Suvorexant Compares to Other Ohio-Available Sleep Medications

Ohio patients have several insomnia pharmacotherapy options. Zolpidem (generic Ambien) is the most widely prescribed, covered by Ohio Medicaid, and available at $10 to $20 per month. Eszopiclone (generic Lunesta) offers a similar cost profile. Both are GABA-A receptor modulators with well-documented risks of complex sleep behaviors and next-day impairment 17.

Lemborexant (Dayvigo), the second FDA-approved DORA, gained approval in December 2019 18. A head-to-head trial (SUNRISE-1, N=1,006) compared lemborexant 5 mg and 10 mg against zolpidem extended-release 6.25 mg. Lemborexant 10 mg showed superior sleep maintenance at the primary endpoint, with a mean wake-after-sleep-onset reduction of 10.5 minutes more than zolpidem ER 18. No direct head-to-head trial of suvorexant versus lemborexant has been published.

Trazodone, prescribed off-label for insomnia, is the most common sleep medication in the United States by prescription volume. A Cochrane review found limited evidence supporting trazodone's efficacy for primary insomnia, with only small, short-duration trials available 19. Despite weak evidence, its low cost and Ohio Medicaid coverage make it a frequent first-line choice in practice.

The clinical decision between these agents should account for the patient's comorbidities, prior medication trials, formulary status, and cost. For Ohio Medicaid patients, suvorexant will rarely be the first option due to formulary restrictions.

Transferring a Belsomra Prescription to Ohio

Patients relocating to Ohio can transfer an existing Belsomra prescription from another state. Ohio Administrative Code 4729:5-5-15 permits the transfer of Schedule III through V controlled substance prescriptions between pharmacies, including across state lines 14. The transferring and receiving pharmacies must both document the transfer, and the prescription can be transferred only once.

If your current prescription has no refills remaining, you will need a new prescription from an Ohio-licensed provider. This is where telehealth offers convenience: a video visit with a new Ohio provider, along with records from your previous prescriber, can yield a new prescription within one business day.

Timeline: Visit to Medication in Hand

For a straightforward case with commercial insurance coverage, the timeline in Ohio is 1 to 5 business days. Day one: telehealth or in-person evaluation, prescription sent electronically. Days two through three: prior authorization review (if required). Days three through five: pharmacy fills and patient picks up or receives delivery. Without prior authorization, many patients have Belsomra in hand within 48 hours of their appointment.

Patients using 503A compounding pharmacies should allow 5 to 10 business days, as compounded preparations require preparation time and shipping logistics 13.